Overview

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Idelalisib